Inspirna is a clinical-stage biopharmaceutical company headquartered in New York City, focused on developing first-in-class small molecule therapeutics to treat cancers with high unmet medical needs, such as RAS mutant colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and endometrial cancer.[1][2][3] It builds novel drugs using its proprietary RNA-DRIVEr™ platform, which identifies RNA-dysregulated cancer drivers like SLC6A8 and LXR for targeting with oral small molecules and biologics, serving oncology patients who lack effective treatments by converting aggressive cancers into manageable conditions.[1][2] The company's lead candidate, ompenaclid (RGX-202), is an SLC6A8 inhibitor in Phase 2 for pan-RAS mutant CRC, while abequolixron (RGX-104) advances in Phase 1b/2 for NSCLC and endometrial cancer; growth momentum includes a $45 million Merck KGaA partnership for global development and multiple clinical catalysts ahead.[1][2][3][4]
Inspirna emerged as a precision oncology player leveraging microRNA mapping and RNA biology to uncover hidden cancer drivers, evolving from early discovery efforts into a clinical-stage biotech with a robust pipeline.[1][2] While specific founders are not detailed in available sources, the company benefits from a strong management team backed by top-tier institutional investors, collaborators like Merck KGaA and Bristol Myers Squibb, and advisors, marking pivotal moments such as the RNA-DRIVEr platform's clinical validation and recent licensing deals.[1][2][3] Early traction built on preclinical insights into targets like creatine kinase B (CKB) in hypoxic tumors, propelling lead programs into Phase 2 trials and partnerships that accelerate global reach.[1][4]
Inspirna rides the wave of precision oncology and RNA therapeutics, capitalizing on surging demand for targeted agents against undruggable drivers like RAS mutations, which affect ~30% of CRC cases amid a $50B+ oncology market.[1][2] Timing aligns with advances in microRNA biology and AI-driven target discovery, amplified by post-pandemic biotech funding recovery and Big Pharma's push for bolt-on assets, as seen in its Merck deal.[2][3] Favorable forces include regulatory nods for orphan oncology indications and combo therapies with docetaxel/checkpoints, positioning Inspirna to influence the ecosystem by validating RNA platforms for small molecules in solid tumors.[1][4]
Inspirna's near-term catalysts—Phase 2 ompenaclid data readouts and Phase 1b/2 abequolixron progress—could drive partnerships or IPO, fueled by RNA tech's expansion into ADCs like RGX-019.[1][2][4] Trends like multi-omics integration and hypoxia-targeting will shape its path, potentially evolving it into a multi-asset leader in metastatic cancer if efficacy holds in RAS/NSCLC niches.[1][3] As a nimble clinical player with elite backers, Inspirna exemplifies biotech's shift toward platform-driven, patient-centric innovation, poised to redefine untreatable cancers as chronic manageables.[2]
Inspirna has raised $55.0M in total across 1 funding round.
Inspirna's investors include venBio, Vivo Capital.
Inspirna has raised $55.0M across 1 funding round. Most recently, it raised $55.0M Series D in July 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2022 | $55.0M Series D | venBio, Vivo Capital |
